Evaluate the effect of anti VEGF injection on postoperative vitreous rebleeding during perioperative period of proliferative diabetic retinopathy

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000031400

Enrollment

Unknown

Registered

2020-03-30

Start date

2020-04-01

Completion date

Unknown

Last updated

2020-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Retinopathy

Interventions

experimental group:Ranibizumab

control group:none

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. PDR patients diagnosed as proliferative diabetic retinopathy with clinical stage V and continuous progress; 2. All surgery are finished by experienced retinal ophthalmologist; 3. No age, gender limitation.

Exclusion criteria

Exclusion criteria: 1. Patients with corrected vision of 20 / 40 or better are preferred; 2. Patients with a history of intravitreal injection of anti VEGF drugs used intraocular fillers such as silicone oil or long-term inert gas; 3. Pregnant patients, patients with cancer, nephritis, coagulation dysfunction, etc.; 4. Patients who cannot be followed up.

Design outcomes

Primary

Measure	Time frame
the incidence of postoperative vitreous hemorrhage;Mean change in best-corrected visual acuity;	—

Secondary

Measure	Time frame
the incidence of post-operative NVG;	—

Countries

China

Contacts

Public ContactTao Ma

Shanxi Eye Hospital

beautifyworld@163.com+86 13834601916

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026